GlassScriptPhysician profile
Syed Mustafa
NPI 1164918116
$4,281.89
in general payments reported to CMS, 2019-2025
24 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $599 · 2022: $134 · 2023: $388 · 2024: $1,984 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,274 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,274.05 |
| Education | $274.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $692.51 | 2021-2025 | Xience Skypoint, Perclose Prostyle, Pressurewire |
| Boston Scientific Corporation | $659.29 | 2021-2024 | Avvigo Guidance System, Latitude Communicator Power Supply, Lux-Dx Insertable Cardiac Monitor |
| Shockwave Medical, INC | $393.64 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $366.88 | 2024-2025 | Indigo System, Penumbra System, Ruby Coil |
| Abiomed | $356.67 | 2024-2025 | Impella |
| Stryker Corporation | $169.41 | 2025 | Clottriever Bold Catheter, Revcore Thrombectomy Catheter, Venacore Thrombectomy Catheter |
| Astrazeneca Pharmaceuticals LP | $146.04 | 2023-2025 | Farxiga, Wainua, Lokelma |
| Cook Medical LLC | $145.56 | 2024-2025 | Zilver Vena, Zilver Ptx |
| Medtronic, INC. | $141.54 | 2024-2025 | In.Pact Av, Silverhawk, Hawkone |
| Novartis Pharmaceuticals Corporation | $130.43 | 2024-2025 | |
| Cordis US Corp. | $127.37 | 2025 | Mynx Control Venous |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.05 | 2023 | Jardiance |
| Scpharmaceuticals INC. | $118.46 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.20 | 2023-2025 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $90.60 | 2022-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $87.99 | 2021 | |
| Pfizer INC. | $76.28 | 2025 | |
| Amgen INC. | $74.51 | 2024 | Repatha |
| Chiesi USA, INC. | $70.29 | 2024 | Kengreal |
| Janssen Pharmaceuticals, INC | $66.10 | 2022 | |
| Biotronik INC. | $62.14 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.35 | 2025 | Eliquis |
| Merck Sharp & Dohme LLC | $23.68 | 2025 | Verquvo |
| Kestra Medical Technology Services, INC. | $16.90 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.